Population and methods: 203 patients were included from june 2007 to june 2008. 61 for the fibrinolysis group and 142 for the PPCI group. All patients benefited of a clopidogrel loading dose (300 mg or 600 mg) and aspirine (250 mg). Tenecteplase was the only fibrinolytic used. Enoxaparine was given with a fixed intraveinous bolus (30 mg)and a subcutaneous dose (0,1 mk/kg). 30 day and 1 year data were obtained using data analysis or phone call contact with patient, GP or cardiologist.
Results: 1 month mortality is 4,4% and 1 year mortality 5,9%. IIb/IIIa GPI have 81% prescription rate. There is no significant difference in term of events between the PPCI group and the fibrinolysis group. Shock, severe bleedings, longer ischemia times were predictive for events in the follow up.
Conclusion:
On a « real life » STEMI population, enoxaparin use shows very similar results to the one oberved in studies and registry with enoxaparin use in term of ischemic and hemorragic events. Thus , our enoxaparin protocol provide adequate anticoagulation simple to provide in pre hospitalary settings indifferently of the reperfusion treatment realised.
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Cytochrome P450 2C19 polymorphism in patients treated with clopidogrel after percutaneous coronary intervention Leila Abid [Orateur] (1), L Laroussi (1), Nouha Abdelmoula (2), Rania Abdelhédi (3), Najla Kharrat (3), Amine Bahloul (1), Mourad Hentati (1), Samir Kammoun (1) (1) Hôpital Hédi Chaker, Cardiologie, Sfax, Laboratoire d 'Histologie , FMS, Sfax, CBS Center , Sfax, Tunisie Background: Clopidogrel and low-dose aspirin have become the mainstay oral antiplatelet regimen to prevent recurrent ischaemic events after acute coronary syndromes or stent placement. The frequent genetic functional variant 681 G>A (*2) of cytochrome P450 2C19 (CYP2C19) is an important contributor to the wide variability between individuals of the antiplatelet effect of clopidogrel. We assessed whether the CYP2C19*2 polymorphism affected long-term prognosis of patients who were chronically treated with clopidogrel.
Methods:
Between May 2009, and september 2010, 100 patients who underwent a percutaneous coronary intervention (PCI) and were exposed to clopidogrel treatment for at least one month, were enrolled in our study. They underwent CYP2C19*2 determination. The primary endpoint was a composite of death, myocardial infarction, and urgent coronary revascularisation occurring during exposure to clopidogrel.
Results: Median clopidogrel exposure time was 6,67+/-6,38 months. Baseline characteristics were balanced between carriers (heterozygous *1/*2, n=23) and non-carriers (n=77) of CYP2C19*2 variant. The primary endpoint occurred more frequently in carriers than in non-carriers (18,2% versus 5,3% p=0·075). No significant differences were noted between the two groups regarding the occurrence of stent thrombosis.
Conclusion.
The CYP2C19*2 genetic variant is a major determinant of prognosis in patients who are receiving clopidogrel treatment after PCI.
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Mediterranean diet decrease homocysteine levels and increase thiolactonase activities in elderly patients at high risk of cardiovascular disease Sonia Hammami [Orateur] , Nadia Koubaa, Amel Nkbi, Soumira Mehri, Mohamed Hammami
Faculté de Médecine Monastir, Nutrition Humaine et Désordres Métabo-liques, Monastir, Tunisie
Background: Food items might have a synergistic and antagonistic effect on health. The Mediterranean diet has long been associated with lower incidence of cardiovascular disease. Elevated blood homocysteine is a risk factor for cardiovascular disease. Thiolactonase; the antioxidant enzymatic component of HDL plays a crucial role in metabolizing homocysteine thiolactone and reducing homocysteine endothelial damages.
Objective: A total of 53 elderly coronary artery disease patient were recruited and divided into diabetic patient (n= 27; age= 68.3years) and non diabetics (n=26; age= 68.7 years). We evaluated plasma homocysteine levels (tHcy); thiolactonase activity (HTase) and studied the effects of adherence to a Mediterranean diet on them.
Methods: tHcy was determined by a validated highly sensitive and accurate capillary gas chromatography mass spectrometry method (GC-MS); HTLase was estimated by a commercially available kit assay. Dietary intakes were evaluated by a validated food frequency questionnaire Results: Significantly higher tHcy levels were found in diabetic patients as compared to non diabetic (18.5 μmol/L (15-24) vs. 15.8 (14-17); p=0.05) associated to lower HTase activities (266.8U/L (162-365) vs. 327.4 (240 -406); p=0.05). Moreover, in the diabetic tHcy levels were negatively associated with thiolactonase activities (r=-0.63; p-0.00). In this group, Mediterranean diet
Results
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reduced diastolic blood pressure (r=-0.55; p=0.01). In the non diabetic group, tHcy levels were negatively correlated with HTase activities (r=0.75; p=0.00) and diet score (r=-0.70; p=0.01) while HTase activities were positively correlated with diet score (r= 0.75; p= 0.00).
Conclusion:
Elevated homocysteine in diabetic patients may partly be explained by the diminished HTase and could be considered as an additional risk factor for cardiovascular events. Adherence to Mediterranean diet could be the first efficient step to prevent these complications.
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Left main coronary stenting in a non surgical octogenarian population: a possible approach Ziad Dahdouh [Orateur] , Vincent Roule, Mathieu Bignon, Guillaume Malcor, Rémi Sabatier, Thérèse Lognoné, Gilles Grollier CHU de Caen, Caen, France Aims. Coronary artery bypass grafting is conventionally considered the standard treatment for significant left main coronary artery (LMCA) disease. The management of severe coronary artery disease in the octogenarians is still highly debated. The aim of this study was to appreciate safety and effectiveness of percutaneaous coronary intervention (PCI) in octogenarians who were denied by the heart team for surgical revascularization.
Methods and Results. The study included 70 consecutive patients t80 years of age who had undergone PCI for the treatment of LMCA and who were primary denied by our center's heart team for surgical revascularization. In our study mean age was 83.4 ± 2.6 years [range 80-89]. Mean Euroscore was 21.1 ± 16.7 and mean Syntax score was 28.6 ± 8.7. Ten (14%) were treated with LMCA PCI in the context of ST-segment Elevation Myocardial Infarction (STEMI). Overall in-hospital mortality was 11%. There were two cases of fatal stent thrombosis at 2 and 7 days respectively after DES implantation. Mean follow-up time was 27.2 ± 24.9 months [range 4-80 months]. Overall mortality at the end of follow-up was 28%. Cardiac death was found in 18 patients and 2 patients died from terminal renal insufficiency. 2 other patients (3%) presented with a new STEMI, 7 (10%) with a new non-STEMI, 13 (19%) with heart failure and 2 (3%) had minor hemorrhage. There was a percutaneous target vessel revascularization in 7 (10%) patients. During follow-up, the total major adverse cerebral and cardiovascular event (MACCE) was 48.5%. Distal LMCA disease and male sex were independent factors predicting mortality (p<0.05).
Conclusions. Stent implantation was technically feasible and relatively safely applied for the treatment of LMCA disease in octogenarian who were refused for surgery and who represented a high risk population for PCI and coronary events. Despite a high rate of MACCE, the clinical long term outcome seems good for this specific population with heavy basal status. Background: Reduced concentrations of clopidogrel active metabolite have been associated with diminished platelet inhibition and higher rates of adverse cardiovascular events. Paraoxonase-1 (PON1) has recently been proposed as a key enzyme for clopidogrel metabolic activation. We tested the effects of PON1 polymorphisms on clopidogrel pharmacokinetics (PK) and pharmacodynamics (PD), and the occurrence of cardiovascular outcomes in young post-MI patients treated with clopidogrel.
Methods and Results:
We genotyped PON1 (Q192R and L55M) and CYP2C19 variants in 106 patients enrolled in the PK/PD CLOVIS-2 trial. Patients were randomly exposed to 300mg or 900mg clopidogrel loading dose in a cross-over study design. Clopidogrel active metabolite isomer H4 (clopi-H4) and platelet function testing were measured serially post-loading dose. There was no significant association between PON1 Q192R or L55M and clopi-H4 formation or antiplatelet response to clopidogrel following either loading dose. Using multivariable linear regression analyses, the CYP2C19*2 allele was the only predictor of clopi-H4 generation and platelet response irrespective of the platelet function assay. CYP2C19 loss-of-function but not PON1 variants were significantly associated with increased risk of major cardiovascular events (death, myocardial infarction and urgent coronary revascularization) occurring during long-term clopidogrel exposure in 371 young post-MI patients (<45 years) enrolled in the AFIJI cohort: CYP2C19 
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Magnetocardiographic indices in assessment of patients with myocarditis and acute STEMI
